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Abstract.  Transforming growth factor-/31 (TGF-/31) 
and TGF-fl2  were found to be potent mitogens for 
purified rat Schwann cells, each stimulating DNA syn- 
thesis in quiescent cells and also increasing their 
proliferation rate. Half-maximal stimulation of DNA 
synthesis occurred at ,'o0.1 ng/ml TGF-fll or TGF-/~2. 
Mitogenic stimulation by TGF-fll and TGF-~2 was en- 
hanced by forskolin, which activates adenylate cyclase, 
at concentrations up to 0.5 #M forskolin. However, at 
5 #M forskolin, the synergistic interaction between 
forskolin and TGF-/31 was abolished. These results are 
in contrast to the observed synergy between forskolin 
and another Schwann cell mitogen, glial growth factor 
(GGF).  Both 0.5 and 5 gM forskolin were found to 
enhance the stimulation of DNA synthesis by partially 
purified GGF (GGF-CM). As well as being function- 
ally distinct, TGF-fll and GGF-CM activities were 
also physically separable by chromatography on a Su- 
perose 12 gel permeation column. Thus, TGF-/31 and 
f12 are rat Schwann cell mitogens, and Schwann cells 
are one of the few normal cell populations to respond 
mitogenically to TGF-~. 
CHWANN cells are the glial,  or "support" cells of the 
peripheral nervous system. During embryogenesis, they 
migrate along growing nerve axons, proliferate, and syn- 
thesize a basal lamina consisting predominantly of laminin, 
collagen, and proteoglycans (Tunpl and Martin,  1981). Even- 
tually they ensheathe the axons, and myelinate larger axons 
(Webster and Favilla, 1984). In adult animals, Schwann cells 
play an important  role in nerve regeneration  after wDund- 
ing, by reentering the cell division cycle, replacing damaged 
Schwann cells, and synthesizing a new basal lamina and my- 
elin (Salzer and Bunge, 1980). In addition, the original basal 
lamina provides a directional ~:ubC along which new axons 
can grow (Aguayo  and Roberts, 1984). 
The factors controlling Schwann cell proliferation during 
embryogenesis and wound healing in vivo are unknown, al- 
though several mitogens have been identified in vitro. The 
best characterized Schwann cell mitogen is glial growth fac- 
tor (GGF),' which has been purified to homogeneity from 
bovine pituitary glands (Lemke and Brockes, 1984). A GGF- 
like factor has also been identified  in human tumors of 
Schwann cell origin (Brockes et al., 1986), suggesting that 
it may play a role as a growth factor in tumorigenesis.  Glia 
maturation factor is also a Schwann cell mitogen (Bosch et 
al.,  1984), and basic  fibroblast growth factor has been re- 
ported to be weakly mitogenic (Rather et al., 1988); whereas 
many other soluble  polypeptide growth factors,  including 
platelet-derived growth factor, epidermal growth factor, and 
nerve growth factor, have been tested and found to be non- 
1. Abbreviations used in this paper:. CaGE glial growth factor; TGF-fl,  trans- 
forming growth factor-fl; [JzsI]UdR, [125112-iododeoxyuridine. 
stimulatory for rat Schwann cells (Raft et al., 1978a; Lemke 
and Brockes, 1984; for review, see Rather et al., 1986). Rat 
Schwann cells are stimulated  to proliferate  by neurites in 
serum-free medium in the absence of added factors (Salzer 
and Bunge, 1980). This mitogenic activity is believed to re- 
side on the netwite cell surface, since axolemmal and PCI2 
membrane fractions stimulate Schwann cell proliferation (Rat- 
net et al., 1986, and references  therein); it can be dissociated 
from membranes, and binds heparin (Rather et al.,  1988; 
DeCoster and DeVries, 1989), but the mitogen has not been 
identified or purified. A mitogenic activity for Schwann cells 
is also secreted  by macrophages that have phagocytosed mye- 
lin-enriched membrane fractions, and it has been suggested 
that this could contribute to the stimulation of Schwann cell 
proliferation  during nerve regeneration (Baichwal  et al., 
1988).  The extracellular  matrix components lamirtin and 
fibronectin also induce DNA synthesis in Schwann cells in 
vitro (Baron-Van Evercooren et al., 1982; McGarvey et al., 
1984), but it is not clear whether they are directly mitogenic, 
or whether they act by binding and presenting growth factors 
(Porter et al., 1987). Finally, agents that increase intracellu- 
lar cAMP levels, such as cholera toxin and forskolin,  are 
mitogenic for Schwann cells, and synergize with GGF-CM 
(partially  purified  GGF) to stimulate proliferation  (Raft et 
al., 1978b; Porter et al., 1986). However, neither GGF nor 
mitogenic membrane fractions  have been shown to act by 
elevating intracellular cAMP levels (Raft et al., 1978a; Mea- 
dot-Woodruff et al.,  1984). 
A  possible  role of type/3 transforming  growth factors 
(TGF-fis) as growth regulators  for Schwann cells has not 
been reported. The TGF-/3s are a family of  polypeptides, be- 
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tumorigenesis in vivo (for review, see Roberts et al., 1988). 
Most cell types express "rGF-B receptors (Wakefield et al., 
1987), but the action of TGF-/3 on cell proliferation in culture 
varies from inhibition to stimulation, depending on cell type, 
growth conditions, and the growth factors present (for re- 
view, see Moses et al., 1985). Although osteoblasts are mito- 
genically stimulated by TGF-/3 (Centralla et al., 1987; Robey 
et al., 1987), it inhibits the proliferation of most normal cell 
populations (Sporn et al.,  1987). 
To investigate the role of TGF-/3 in Schwann cell develop- 
ment and tumorigenesis, it is important to establish what ac- 
tion, if any, TGF-B has on the growth of Schwann cells. We 
have shown that both TGF-BI and TGF-B2 are potent mito- 
gens for rat Schwann cells in vitro, and that the activity of 
TGF-B can be clearly distinguished from GGF-CM activity. 
Materials and Methods 
Materials 
The  following sources and  materials were used:  tissue culture plastics 
(Costar, Cambridge, MA); batch-tested FCS (Imperial Laboratories Ltd., 
Salisbury, England); poly-(o or L)-lysine hydrrobromide (relative molecular 
mass of  30-70 kD) and rabbit complement (Sigma Chemical Co., St. Louis, 
MO);  DME,  2.5%  trypsin in PBS, and 0.05%  trypsin/0.02%  EDTA in 
modified Puck's saline (Gibco Laboratories, Grand Island, NY); collagen- 
ase (type I)  (Worthington Biochemical Corp.,  Freehold,  NJ);  forskolin 
(Calbiocbem-Behring Corp., San Diego, CA); anti-Thy-l.l IgM (Serotec, 
Oxford, England); [12sI]2-iododeoxyuridine  (Amersham Corp., Arlington 
Heights, IL); highly purified porcine platelet-derived TGF-~I, TGF-B2, and 
purified rabbit anti-'rGF-/3 polyclonal lgG (R&D Systems, Minneapolis,  MN). 
A crude preparation of GGF was prepared according to the methods of 
Lemke and Brockes (1984).  Briefly,  frozen bovine pituitaries (Northeast 
Biomedical Laboratories,  Uxbridge, England) were homogenized and a 
protein precipitate collected at a concentration of between 40-70 % ammo- 
nium sulphate. The ammonium sulphate precipitate was diluted and solubi- 
lized, filtered and concentrated on a  lO-kD tangential flow filter,  dialyzed 
into 0.1 M sodium phosphate (pH 6.0), loaded onto a CM-cellulose column, 
washed with 0.05 M sodium chloride/0.1 M sodium phosphate (pH 6.0), and 
eluted with 0.2 M sodium chloride/0.1 M sodium phosphate (pH 6.0).  The 
active fraction (known as GGF-CM), 0.2-0.3 mg protein/ml, was pooled 
and stored at  -20°C. 
Schwann Cell Culture 
Schwann cells from rat sciatic nerves were isolated using the method of 
Brockes et al. (1979).  Briefly,  sciatic nerves were dissected from rat pups, 
dissociated with 0.1% coUagenase and 2.5% trypsin in DME and plated onto 
poly-lysine-coated tissue culture flasks in DME containing 10% FCS, 100 
U/ml penicillin, and 100 ~tg/rnl streptomycin (PS). After ,,o24 h the medium 
was replaced with fresh medium containing 10 #M 1-/3-D-arabinofuranosyl- 
cytosine. The cells were washed 3--4 d later, and fed with DME containing 
10% FCS, PS, 5 #M forskolin, and 0.5 #g/ml GGF-CM. Once confluent, 
2-3 d later, the cells were detached with 0.05 % trypsin/0.02 % EDTA in 
modified Puck's saline, washed, and treated with mouse monocional anti- 
Thy-l.1  antibody and rabbit complement for 30 min to remove contaminat- 
ing fibroblasts. Schwann cells prepared by this method have been shown to 
be 99.5% pure as determined by immunofluorescent staining for N-CAM, 
laminin and collagen type IV (see also Ridley et al., 1988).  Schwann cells 
were grown on poly-lysine-coated tissue culture plastic (poly-lysine was 
necessary to maintain long-term proliferation of Schwann cells in culture; 
see Porter et al., 1986) in DME containing 10% FCS, PS, 5 #M forskolin, 
0.5 #g/ral GGF-CM, and passaged every 4-7 d as described above. 
Measurement of  Schwann Cell Proliferation 
First passage Schwann cells were seeded onto poly-lysine-coated 24-well 
dishes (Falcon Labware, Oxnard, CA) at lif  t cells/well, in DME contain- 
ing 3% FCS, 1 #M forskolin, and 0.5/zg/ml GGF-CM. After 48 h, cells 
were washed with DME and 3 % FCS/DME containing the appropriate con- 
centrations of TGF-/31, TGF-~2, or forskolin was added. Cells were fed ev- 
ery 2 d. To count cells, triplicate wells were trypsinized and counted with 
a Coulter counter. 
Assay of  Schwann Cell DNA Synthesis 
The method for measuring DNA synthesis was based on that described by 
Raft et al. (1978a).  Cells were cultured in the absence of GGF-CM or for- 
skolin for 2-3 d, then seeded in 96-well plates (Costar) at 10,000 cells/well 
in 100 #l/well DME, 10% FCS. 16-24 h later, growth factors, aliquots from 
column fractions, and forskolin were added to the wells. GGF-CM, TGF-/3 
and forskolin were serially diluted in DME and added to give a constant 
volume of 120 ~tl. A  1-2 #g/ml TGF-/3 stock was prepared in 4 mM HCI, 
1 mg/ml BSA (fatty  acid free), and a 5-raM forskolin stock was prepared 
in DMSO. 5 #1 of each column fraction was added per well, using column 
running buffer as a control. The cells were then incubated for 48 h, 0.2 
#Ci/well [125I]2-iododeoxyuridine  being added for the last 24 h. Medium 
was aspirated, cells detached using 0.05 % trypsin/0.02 % EDTA in modified 
Puck's saline, harvested onto glass fiber filter mats, washed with H20 fob 
lowed by ethanol, and incorporated radioactivity was counted. 
Column Chromatography 
GGF-CM and TGF-/31 were diluted into 50 mM sodium phosphate (pH 6.0), 
loaded onto a Mono S HR 5/5 cation exchange column (Pharmacia Fine 
Chemicals, Piscataway, NJ) and eluted with a 40 m1/40 min linear gradient 
up to 2 M sodium chloride/50 mM sodium phosphate (pH 6.0) buffer. Frac- 
tions were collected into tubes containing 100 #1 BSA in PBS, as carrier 
protein, giving a final concentration of 0.1 mg/ml BSA. 
Gel permeation was carried out on a Superose 12 HR 10/30 column (1% 
0538-01; Pharmacia Fine Chemicals) equilibrated and run in 50 mM sodium 
phosphate, 750 mM sodium chloride (pH 6.1) (running buffer). The column 
was calibrated using bovine thyroglobulin, bovine gamma globulin, chicken 
ovalbumin, horse myoglobin, and vitamin B-12 standards (Bio-Rad Labora- 
tories, Cambridge, MA). 100 ng of TGF-/31 and 100 #g GGF-CM samples 
were run through the column separately, or together, with 35 ml of running 
buffer, and collected in the presence of 0.1 mg/ml carder BSA. 5 #1 samples 
of each fraction were assayed for Schwann cell mitogenic activity, in the 
presence of 0.5 or 5 #M forskolin. 
Results 
TGF-/31 and/32 Are Mitogenic for Schwann Cells 
To test the mitogenic response of rat Schwann cells to TGF-/3, 
serial dilutions of TGF-/31 and TGF-/32 were assayed for their 
ability to stimulate DNA synthesis.  Highly purified porcine 
platelet  TGF-fll  and TGF-/32 were both mitogenic for qui- 
escent  Schwann  cells,  as  determined  by  incorporation  of 
[~25I]2-iododeoxyuridine ([~25I]UdR) (Fig.  1 a).  Half-maxi- 
mal stimulation of DNA synthesis was obtained with TGF-/~l 
at 0.1 ng/ml, and with TGF-/32 at 0.07 ng/ml. Although the 
background  DNA  synthesis  varied  considerably  between 
different experiments,  TGF-/31 consistently  induced a 5-10- 
fold stimulation of DNA synthesis in six independent experi- 
ments. The mitogenic action of both the TGF-/31 and TGF-/32 
preparations  was  inhibited  by  purified  rabbit anti-TGF-/3 
polyclonal IgG (Fig.  1 b); 50 #g/ml IgG completely blocked 
the stimulation of DNA synthesis induced by 1 ng/ml TGF- 
/31, and 10/zg/ml neutralized the action of I ng/ml TGF-/32. 
Similar  concentrations  of this anti-TGF-/3 IgG neutralized 
the action  of TGF-/3 both as a mitogen for AKR-2B cells 
(Keski-Oja et al., 1987), and as an inhibitor of DNA synthe- 
sis on mink lung epithelial cells (as reported by R & D Sys- 
tems);  thus  mitogenic  stimulation  of Schwann  cells  was 
likely to be specifically  induced by TGF-/3 molecules in the 
purified preparations, and not by contaminants. In addition, 
50 ~g/ml of anti-TGF-~t IgG had no effect on the mitogenic 
activity of partially purified GGF (GGF-CM) obtained from 
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Figure I. Stimulation of  DNA synthesis in Schwann  cells by TGF-/51 
and TGF-B2. (a) Serial dilutions of TGF-31 (o) or TGF-/32 (o) 
were added to Schwann cells in microtitre dishes. Induction of 
DNA synthesis was measured by incorporation of [12sI]UdR. (b) 
Serial dilutions of purified rabbit anti-TGF-3 polyclonal IgG were 
added to Schwann cells together with  1 ng/ml TGF-B1 (0), 0.2 
ng/ml TGF-B1 (B), or 1 ng/ml TGF-fl2 (o). Background [IEsI]UdR 
incorporation in control cultures without TGF-B  or antibody is also 
shown.  Values represent  the  mean  of duplicate determinations, 
which each differed by <10% from the mean. 
bovine pituitary glands (data not shown); it is therefore un- 
likely that TGF-/5 and GGF share the common epitope that 
this antibody recognizes on TGF-/5 molecules. 
As well as stimulating DNA synthesis, TGF-B1 and TGF- 
/52 also stimulated the proliferation rate of Schwann cells, as 
measured by increase in cell number over 9 d (Fig. 2). At 
1 ng/ml TGF-31 or TGF-B2, the doubling time in the ex- 
ponential phase of growth was ,,04 d, whereas the doubling 
time of cells without added TGF-3 over the same period was 
longer than 8 d. This concentration of TGF-/5 is in the same 
range as that required to stimulate the growth of osteoblasts 
(Centralla et al., 1987), and of normal rat kidney fibroblasts 
in soft agar (Anzano et al.,  1983). 
TGF-B1 Synergizes with Forskolin in Stimulating 
Schwann Cell Proliferation 
The Schwann cell mitogenic activity in GGF-CM acts syner- 
gistically with agents that increase intracellular cAMP levels 
to stimulate proliferation (Raft et al.,  1978;  Porter et al., 
1986). To establish whether TGF-/5 action could also be en- 
hanced by increasing cAMP levels, the mitogenic activity of 
TGF-3 was tested in combination with forskolin, a diterpene 
drug  that  raises  the  intracellular cAMP  concentration by 
stimulating  adenylate  cyclase  (Seamon  and  Daly,  1981). 
While forskolin alone stimulated DNA synthesis only very 
slightly, in combination with TGF-31  it synergistically in- 
creased the induction of DNA synthesis (Fig. 3 a). However, 
this activity was highly dependent on the concentration of 
forskolin present.  Synergy between TGF-B1  and forskolin 
was detectable at concentrations as low as 0.005 #M forsko- 
lin,  and maximal stimulation of the TGF-B1  response oc- 
curred at 0.5/zM forskolin. In contrast, 5/zM forskolin did 
not stimulate or slightly suppress the TGF-Bl-induced DNA 
synthesis response in three independent experiments. For ex- 
ample, 0.25 ng/ml TGF-31 induced an approximately five- 
fold stimulation of DNA synthesis in the absence of forsko- 
lin, whereas in 5/~M forskolin DNA synthesis was increased 
only approximately threefold (Fig. 3 a). This pattern of re- 
sponse to different forskolin concentrations was seen at both 
suboptimal and optimal concentrations of TGF-B1 (Fig. 3 b). 
The proliferation rate of Schwann cells in TGF-31  and 
TGF-32 was also enhanced by forskolin, as shown in Fig. 2. 
Forskolin at 0.5/zM synergized with both TGF-31 and TGF- 
/52 in stimulating Schwann cell proliferation, decreasing the 
doubling time during exponential growth from 4  to 2 d. 
The critical dependence of the TGF-~ mitogenic response 
on forskolin concentration contrasts with the synergy ob- 
served between GGF-CM and forskolin. In the presence of 
both  suboptimal  and  optimal  mitogenic concentrations of 
GGF-CM, 5 #M forskolin was found to be more stimulatory 
than  0.5  /zM  forskolin  (Fig.  3  c).  The  responses  of rat 
Schwann cells to GGF-CM and TGF-B1 can thus be distin- 
guished on the basis of their synergistic action with forsko- 
lin,  suggesting that these two mitogenic activities act via 
different mechanisms.  Since the action of a third Schwann 
cell mitogen, glia maturation factor, is not enhanced by in- 
creased intracellular cAMP levels (Bosch et al.,  1984), the 
synergism of TGF-/51 with  forskolin also  distinguishes  it 
from glia maturation factor. 
Separation of TGF-[31 and GGF-CM Activities by 
Column Chromatography 
The results above provide a biological assay for distinguish- 
ing TGF-B from the Schwann cell mitogcnic activity in GGF- 
CM, through their differential mitogenicity in combination 
with forskolin on Schwann cells. However, to distinguish the 
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Figure 2.  Stimulation of Schwann cell proliferation by TGF-3 and 
forskolin. Cells were grown in 3 % FCS/DMEM (x), or 3 % FCS/ 
DMEM supplemented with 1 ng/ml TGF-B1 (o), 1 ng/ml TGF-32 
(o), 0.5/zM forskolin (A), 1 ng/ml TGF-/~I and 0.5/zM forskolin 
(B),  1 ng/ml TGF-~2 and 0.5  #M  forskolin ([:3). Cell numbers 
were determined at the times indicated. Each value represents the 
mean of  triplicate cultures, which differed by <10% from the mean. 
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Figure 3. DNA synthesis in Schwann cells in the presence of forsko- 
lin and either TGF-/31 or GGF. (a) Schwann cells were exposed to 
serial dilutions of forskolin in the presence of 0 ng/ml TGF-/31 (o), 
0.0025 ng/ml TGF-/31 (m), 0.025 ng/ml TGF-/31 (A), or 0.25 ng/ml 
TGF-/31 (o). Cells were also incubated with serial dilutions of TGF- 
/31  (b),  or GGF-CM (c),  in the presence  of 0 #M forskolin (o), 
0.05 #M forskolin (A), 0.5 #M forskolin (m), or 5 #M forskolin 
(e). Induction of DNA synthesis was measured by incorporation 
of ['25I]UdR. Values represent  the mean of duplicate determina- 
tions, which differed by <10% from the mean. Similar results were 
obtained in two independent experiments. 
identify TGF-/~ in the presence of other factors produced by 
Schwann  cell  tumors  and  tumor cell  lines,  a  method  for 
separating TGF-/3 from GGF-CM activity was devised. GGF- 
CM  obtained from bovine pituitary glands (see Materials 
and Methods) and purified porcine platelet TGF-/31 were run 
both on a Mono S cation exchange column and on a Superose 
12 gel permeation column. To distinguish GGF-CM and TGF- 
/31 activities, fractions were tested in combination with 0.5 
#M or 5/zM forskolin for their ability to induce DNA synthe- 
sis in Schwann  cells.  TGF-/31 and GGF-CM activities co- 
eluted from a Mono S column under the conditions described 
(Materials and Methods, data not shown), but were clearly 
separable on a Superose 12 column (Fig. 4). TGF-/~I showed 
unusual behavior on this column,  as its migration was re- 
tarded, with activity eluting at the end of the column, peak- 
ing in fractions 28-29 (Fig. 4 a); whereas GGF-CM activity 
peaked in fraction 17, with no detectable activity in fractions 
28-29 (data not shown). A mixture of GGF-CM and TGF-/31 
was separated into two activities (Fig. 4 b), the first peaking 
at fraction 17, and the second at the end of the column, with 
highest activity in fractions 28-29.  The first peak of mito- 
genic activity was detected in the Schwann cell DNA synthe- 
sis assay with 0.5  #M  forskolin, and gave greater activity 
with 5 #M forskolin, thus displaying the same properties as 
GGF-CM. The second activity was detected in the presence 
of 0.5 #M forskolin, but not with 5 #M forskolin, and was 
therefore identified as TGF-/31. This separation method should 
allow the detection and identification of TGF-/3-1ike factors, 
in tumor samples and in conditioned medium from cell lines, 
which stimulate Schwann cell proliferation. 
Discussion 
TGF-/3  can act either  as an inhibitor or stimulator of cell 
proliferation, depending on both cell type and growth condi- 
tions (for review, see Moses et al., 1985). Since the respon- 
siveness of a cell type to growth stimulatory and inhibitory 
factors can alter upon expression of oncogenes and transfor- 
mation (Armelin et al., 1984; Stern et al., 1986; Jetten et al., 
1986), it is important to study the behavior of normal cells 
towards factors to understand their potential roles in develop- 
ment,  regeneration,  and  disease.  Our results  demonstrate 
that both TGF-/31 and TGF-/32 are mitogens for normal rat 
Schwann cells in vitro. Of other normal cell populations that 
have been studied, osteoblasts are one of the few to be stimu- 
lated by TGF-/3 (Centralla et al.,  1987;  Robey et al.,  1987). 
In contrast, TGF-/5 inhibits the proliferation of most normal 
cell types,  including  keratinocytes,  B  and T  lymphocytes, 
bronchial epithelial cells and endothelial cells (Sporn et al., 
1987,  and references therein).  It is thus important to have 
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Figure 4.  Separation  of TGF-~I  from GGF-CM  on Superose  12. 
100 ng TGF-~I (a), or a mixture of 100 ng TGF-/31 and  100 #g 
GGF-CM (b), were run on a Superose 12 column as described in 
Materials and Methods. Fractions were collected with carrier BSA 
and assayed for mitogenic activity on Schwann cells in the presence 
of 0.5 #M forskolin (o), or 5/zM forskolin (o). The experiment 
in a was performed on a different Schwann cell population to that 
in b. The broadening of the TGF-/31-specific  peak in b has been ob- 
served in several independent experiments, and occurred after stor- 
age of the TGF-fll preparation,  whereas a sharper peak, as in a, 
was obtained with fresh TGF-/31 stock. 
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basis for its pleiotropic actions. 
TGF-/~I acts synergistically with forskolin,  which stimu- 
lates adenylate cyclase, to stimulate Schwann cell prolifera- 
tion, and experiments are in progress to investigate its action 
in the presence of other Schwarm cell mitogens. In addition, 
it is possible that serum factors, or autocrine factor(s) secret- 
ed by Schwann cells (Porter et al., 1987), may synergize with 
TGF-/~. Preliminary evidence suggests that TGF-ffl induces 
DNA synthesis '~8 h later than GGF-CM in quiescent Sehwann 
cells (J. Davis, unpublished data).  One explanation for this 
delayed action of TGF-/~ could be that it stimulates the Schwarm 
cells to secrete an autocrine growth factor, for example GGF 
or glia maturation  factor (Bosch et al.,  1984;  Lim et ai., 
1988). Such an action for TGF-/~ has been described in the 
mouse cell line AKR-2B, where TGF-fl stimulates secretion 
of a PDGF-like factor, which acts as a direct mitogen (Leof 
et al.,  1986). 
TGF-/~s  are  a  group of closely related  polypeptides,  of 
which  four  members  have  been  cloned  (Derynck  et  al., 
1985; Madisen et al.,  1988; ten Dijke et al., 1988; Derynck 
et al., 1988; Jakowlew et al., 1988). The two factors TGF-/~I 
and TGF-/ff2 have been best characterized,  and are 71% ho- 
mologous in amino acid sequence. Little is known about pos- 
sible differential functions of the two factors in vivo, but a 
few studies have directly compared the actions of TGF-~I 
and TGF-ff2 in vitro. In adipocytes, both inhibit expression 
of differentiation-specific  genes  (Cheifetz  et  al.,  1987), 
whereas DNA synthesis in aortic endothelial cells is strongly 
inhibited by TGF-/~I but not TGF-~2 (Jennings et al., 1988). 
We have shown that both TGF-/~I and TGF-/~2 stimulate rat 
Schwann cell DNA synthesis and proliferation with similar 
potency. 
Since TGF-/3 is a mitogen for Schwann cells, it is possible 
that autocrine secretion of TGF-/$ could be involved in the 
development of Schwann cell tumors.  Many cell types have 
been shown to secrete TGF-/3 (Assoian et al.,  1985), most 
of which is in an inactive, latent form that can be activated 
by proteolysis or acid  treatment  (Lawrence  et al.,  1984; 
Lyons et al.,  1988). As nearly all cell types express TGF-/~ 
receptors (Wakefield et al., 1987), it has been postulated that 
activation of latent TGF-/$ could be important in controlling 
TGF-/3 action in vivo (Roberts et al.,  i988).  Schwann cells 
which secreted TGF-/~, and were able to activate it, would 
stimulate their own proliferation, thus escaping the require- 
ment for exogenous mitogenic factors. Northern analysis has 
shown that rat Schwann cells contain TGF-/~ mRNA (A. Rid- 
ley, unpublished data), thus it is probable that normal Schwann 
cells in culture synthesize latent TGF-/~. The ability to acti- 
vate TGF-~ may be linked to the transformation process, and 
could play a crucial role in the development of a tumorigenic 
phenotype.  A  Schwann  cell  population  has  been  isolated 
which grows in the absence of added growth factors in vitro 
(Porter et al.,  1987).  These cells produce a  Schwann cell 
mitogen, and are tumorigenic in nude mice (Langford, et al., 
1988). Transformed Schwann cells expressing the oncogenes 
SV40 large T and v-Ha-ras can also proliferate in the absence 
of added mitogens (Ridley et al.,  1988). It is possible that 
TGF-/~ could be acting as an autocrine factor in both these 
cases. In addition, a number of tumors of Schwann cell origin 
contain polypeptide factor(s) mitogenic for normal Schwann 
cells (Brockes et al.,  1986), and it was suggested that these 
tumors might secrete GGF. It should now be possible to iden- 
tify whether TGFo/$ is a major mitogen present in Schwann 
cell tumor extracts, both by testing for Schwann cell mito- 
genic  activity  in combination  with forskolin,  and also by 
using neutralizing antibodies to TGF-~. In addition, the na- 
ture of the Schwann cell mitogen(s) in neurite membranes is 
not known (Ratner et al., 1986; DeCoster and DeVries, 1989), 
and a possible relationship to either GGF or TGF-/3 could 
also be investigated by these methods. 
Aside from its effects on cell proliferation,  TGF-/~ can in- 
duce or enhance  the  formation  of extracellular  matrix  in 
many cell types (Sporn et al.,  1987), and there is some evi- 
dence that this action could be involved in wound healing in 
vivo (Roberts et al.,  1988). In vitro, it stimulates the tran- 
scription of both the collagen and fibronectin genes in nor- 
mal rat kidney cells (Ignotz et al.,  1987). In addition, it in- 
hibits the degradation of newly formed matrix proteins, both 
by increasing  the synthesis of protease  inhibitors,  and  by 
decreasing the secretion of certain proteases (Sporn et al., 
1987). Schwann cells are highly specialized for the synthesis 
of extracellular matrix,  and secrete collagen type IV, lami- 
nin,  and heparan proteoglycans that form the basal lamina 
around nerve axons (Timpl and Martin,  1981). It will be im- 
portant to determine whether TGF-/$ enhances extracellular 
matrix production by Schwann cells in vitro, and whether it 
can stimulate expression of myelin-specific proteins such as 
Po and myelin basic proteins (Lemke,  1986). Schwann cells 
present a good model for studying TGF-~ action, since the 
proliferation  and differentiation  of purified  Schwann  cells 
can be studied in vitro. TGF-/3s could play a specific role in 
controlling Schwann cell function in vivo, both stimulating 
proliferation and concomitantly promoting synthesis of dif- 
ferentiation-specific extracellular matrix molecules. Such a 
role would be relevant to peripheral nerve regeneration after 
wounding, and also to the development of nerve tracts during 
embryogenesis. 
We thank Dr. Andy Goodearl for generously providing the GGF-CM used 
in these experiments. 
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